Chongkai Wang

发表

Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome.

M. Fakih, Chongkai Wang, J. Sandhu, 2018, Journal of gastrointestinal oncology.

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.

Jun Gong, M. Fakih, P. Chu, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.

M. Fakih, Peter P. Lee, J. Gong, 2018, Journal of gastrointestinal oncology.

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer

Prakash Kulkarni, R. Salgia, Chongkai Wang, 2019, Molecular therapy oncolytics.

A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.

M. Fakih, J. Gong, Chongkai Wang, 2022, Clinical colorectal cancer.

IL-2 and IL-6 cooperate to enhance the generation of influenza-specific CD8 T cells responding to live influenza virus in aged mice and humans

G. Kuchel, S. Swain, Chongkai Wang, 2016, Oncotarget.

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

M. Fakih, Chongkai Wang, Jingran Ji, 2022, OncoTargets and therapy.

Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer

M. Fakih, Chongkai Wang, J. Sandhu, 2022, JAMA network open.

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

M. Fakih, Peter P. Lee, Chongkai Wang, 2021, JAMA network open.

RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance.

V. Miller, M. Fakih, Siraj M. Ali, 2019, Journal of Clinical Oncology.

Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.

M. Fakih, Chongkai Wang, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors.

M. Fakih, Chongkai Wang, J. Sandhu, 2019, Journal of gastrointestinal oncology.

Presence of Concurrent TP53 Mutations Is Necessary to Predict Poor Outcomes within the SMAD4 Mutated Subgroup of Metastatic Colorectal Cancer

M. Fakih, Chongkai Wang, J. Sandhu, 2022, Cancers.

Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy

J. Dang, M. Fakih, Chongkai Wang, 2022, Science advances.

Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.

M. Kortylewski, S. Sampath, Peter P. Lee, 2020, The Journal of clinical investigation.

Targeting KRAS in Colorectal Cancer

M. Fakih, Chongkai Wang, 2021, Current Oncology Reports.

Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?

M. Fakih, Chongkai Wang, 2021, Expert opinion on biological therapy.

Wild-type APC is associated with poor survival in metastatic microsatellite stable colorectal cancer.

M. Kahn, M. Fakih, A. Goel, 2020, The oncologist.

The non-muscle-myosin-II heavy chain Myh9 mediates colitis-induced epithelium injury by restricting Lgr5+ stem cells

B. Zhao, Yehua Li, Chongkai Wang, 2015, Nature Communications.

Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.

M. Fakih, Peter P. Lee, M. Cho, 2019, The Journal of clinical investigation.

Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases.

M. Fakih, L. Thornblade, Y. Fong, 2021, American journal of surgery.

Oncogenic Function of DACT1 in Colon Cancer through the Regulation of β-catenin

W. Fu, Chongkai Wang, Chao-lai Ma, 2012, PloS one.

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.

M. Fakih, Chongkai Wang, Jun Wu, 2020, Clinical colorectal cancer.

A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases.

M. Fakih, H. Yin, Peter P. Lee, 2019, The oncologist.

Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.

M. Fakih, Chongkai Wang, J. Sandhu, 2023, JAMA oncology.

Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model

M. Fakih, Chongkai Wang, Misagh Karimi, 2020, Journal of clinical medicine.

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer

M. Fakih, Chongkai Wang, J. Sandhu, 2020, The oncologist.

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS

A. Bild, Hanlin Gao, Prakash Kulkarni, 2019, bioRxiv.

Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.

M. Fakih, Chongkai Wang, J. Sandhu, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer.

M. Fakih, Chongkai Wang, J. Sandhu, 2023, Cancer treatment and research communications.

Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series.

Chongkai Wang, Ji Jingran, Wang Chongkai, 2021, Clinical colorectal cancer.